7,309 examinees pass medical technologist board exam in March

PRC: 7,309 pass medical technologist board exam in March 2024

/ 10:39 AM March 27, 2024

PRC: 7,309 examinees pass medical technologist board exam in March 2024

INQUIRER FILE PHOTO

MANILA, Philippines — Some 7,309 out of 9,068 examinees have passed the Medical Technologists Licensure Examination in March 2024, the Professional Regulation Commission (PRC) said on Wednesday.

READ: PRC releases board results for mechanical engineering, plant mechanics 

Article continues after this advertisement

A graduate from Cebu Doctors University topped the list of passers with a 93 percent rating.

FEATURED STORIES

The topnotcher, Jeency Aguilar Pilapil, is among the three graduates from Cebu Doctors University who made it to the top 10 highest scorers in the licensure examination.

Pilapil is followed by Jed Ataban Cangsan from Saint Louis University, with a rating of 92.8 percent.

Article continues after this advertisement

Third place is Ralph Jason Datu Tulmo, a Riverside College graduate who scored 92.7 percent.

Article continues after this advertisement

The rest of the top ten lists in the March 2024 Medical Technologists Licensure Examination are as follows:

PRC: 7,309 pass medical technologist board exam in March 2024

The PRC likewise said that Cebu Doctors University and Notre Dame of Marbel University both topped the list of best-performing schools in the licensure examination, with a 100 percent passing rate.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Board exam, PRC

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.